10,000 adults to be tracked for RSV – could pave way for vaccine decisions
NCT ID NCT07321314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will track 10,000 adults in Hong Kong with respiratory symptoms to measure how often RSV causes illness and how severe it gets. Researchers will collect nose and throat samples and blood tests over several weeks. The goal is to fill knowledge gaps about RSV in adults and help guide future vaccine use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide crucial data on how common and severe RSV is in adults, helping health officials decide whether to fund vaccines for high-risk groups.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any therapy or vaccine, so it cannot directly improve health. Results depend on accurate reporting and may not apply to other regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese University of Hong Kong
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new model help botswana shield infants from RSV?
- Can a simple breath test catch flu in High-HIV regions?
- Scientists deliberately infect older adults with RSV to unlock immune secrets
- Could vitamin d levels predict wheezing after bronchiolitis?
- New pill could help babies fight RSV faster
- Could a simple vaccine slash COPD attacks?